Notably, we also found that PARP inhibitors, which have shown unprecedented activity against ovarian tumors and other tumors that have mutated BRCA1 and BRCA2[40]–[43], remarkably sensitized ovarian cancer cells to FdUrd but not 5-FU [17]. This evidence concerns the gene BRCA2 and ovarian carcinoma.